NCT02605538

Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Karolinska University Hospital · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Accepted

Summary

CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization has been complete.

Detailed description

Initially, healthy volunteers will be vaccinated to be compared with patients' antibody response to hepatitis A and B vaccine. The connected part of this study is to vaccinate children suffering from latent tuberculosis against hepatitis B and to measure whether the immunization is related to specific interferon gamma response against Mycobacterium tuberculosis.

Conditions

• Cystic Fibrosis
• Hepatitis A
• Hepatitis B
• Tuberculosis

Interventions

Type	Name	Description
BIOLOGICAL	Vaccination with vaccine against hepatitis A and B	Vaccination against hepatitis A and B

Timeline

• Start date: 2015-09-01
• Primary completion: 2023-12-01
• Completion: 2025-12-31
• First posted: 2015-11-16
• Last updated: 2024-03-18

Locations

1 site across 1 country: Sweden